Payment overview · 2025
General Payments
$2,330.73
121 reported records · 26 companies
Healthcare provider profile · identity verified
Magdy George Wanis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ST CLAIR SHORES, MI · NPI 1346353224
Verified facts
What the public records show
CMS Open Payments records show Magdy George Wanis, MD received $2,330.73 in general payments during 2025 across 121 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lantus by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $529.39 | 22.7% | 31 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $324.84 | 13.9% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $293.36 | 12.6% | 17 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $260.49 | 11.2% | 12 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $180.22 | 7.7% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.13 | 3.2% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $57.59 | 2.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $56.30 | 2.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55.14 | 2.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.01 | 2.2% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $49.90 | 2.1% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $49.87 | 2.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.84 | 1.8% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $40.14 | 1.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.58 | 1.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.87 | 1.3% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $28.23 | 1.2% | 1 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.09 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.57 | 1.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.37 | 0.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.27 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.31 | 0.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.55 | 0.8% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $15.06 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.93 | 0.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $13.68 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,330.73 | 121 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $529.39 | 31 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $302.91 | 13 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $180.22 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $136.18 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $132.88 | 10 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.31 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $121.71 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $120.21 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $61.28 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $57.59 | 3 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $56.30 | 2 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $56.30 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $55.14 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.01 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $49.90 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $49.87 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $49.87 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.84 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $33.58 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $33.58 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $33.58 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.87 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $28.23 | 1 | 2025 |
Source payment records
|
|||||
| Empaveli Normalized: empaveli |
Drug | Apellis Pharmaceuticals, Inc. | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 111 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
111 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 610 | 122 |
| Losartan Potassium | Losartan Potassium | 287 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 245 | 51 |
| Omeprazole | Omeprazole | 242 | 47 |
| Alprazolam | Alprazolam | 241 | 46 |
| Trazodone Hcl | Trazodone Hcl | 219 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 213 | 49 |
| Metformin Hcl | Metformin Hcl | 187 | 41 |
| Lisinopril | Lisinopril | 183 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 31 |
| Divalproex Sodium | Divalproex Sodium | 156 | 11 |
| Gabapentin | Gabapentin | 154 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 32 |
| Potassium Chloride | Potassium Chloride | 131 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 111 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 16 |
| Furosemide | Furosemide | 100 | 32 |
| Simvastatin | Simvastatin | 99 | 18 |
| Meloxicam | Meloxicam | 98 | 19 |
| Tramadol Hcl | Tramadol Hcl | 98 | 24 |
| Benztropine Mesylate | Benztropine Mesylate | 92 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | suppressed |
| Ibuprofen | Ibuprofen | 91 | 25 |
| Ozempic | Semaglutide | 91 | 16 |
| Haloperidol | Haloperidol | 88 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 87 | 16 |
| Naproxen | Naproxen | 87 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 84 | 13 |
| Fluphenazine Hcl | Fluphenazine Hcl | 84 | suppressed |
| Lorazepam | Lorazepam | 80 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 77 | suppressed |
| Carvedilol | Carvedilol | 74 | 13 |
| Baclofen | Baclofen | 73 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 72 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 12 |
| Meclizine Hcl | Meclizine Hcl | 59 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 13 |
| Eliquis | Apixaban | 57 | suppressed |
| Aripiprazole Odt | Aripiprazole | 56 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 11 |
| Diazepam | Diazepam | 54 | suppressed |
| Risperidone | Risperidone | 54 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 11 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 15 |
| Lidocaine | Lidocaine | 51 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 13 |
| Spironolactone | Spironolactone | 46 | 12 |
| Metformin Hcl Er | Metformin Hcl | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 11 |
| Pregabalin | Pregabalin | 44 | suppressed |
| Famotidine | Famotidine | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | 11 |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Ondansetron Odt | Ondansetron | 41 | 18 |
| Azelastine Hcl | Azelastine Hcl | 39 | 13 |
| Azithromycin | Azithromycin | 39 | 32 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Hydrocortisone | Hydrocortisone | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 22 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Rybelsus | Semaglutide | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 28 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Austedo | Deutetrabenazine | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 15 |
| Dermacinrx Lidocan | Lidocaine | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Wegovy | Semaglutide | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Lamotrigine Odt | Lamotrigine | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Flunisolide | Flunisolide | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,330.73 · 121 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, AIRSUPRA, AREXVY, ARISTADA, AUSTEDO XR, BREZTRI, CAPLYTA, CLOTTRIEVER BOLD CATHETER, COMIRNATY, Cologuard Collection Kit, Empaveli, Fabhalta, Flector, GATTEX, GEMTESA, INGREZZA, INSPIRE, JARDIANCE, Kerendia, LYBALVI, Licart, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, TRELEGY ELLIPTA, TZIELD, Tirosint, UBRELVY, VOQUEZNA, VRAYLAR, Vanrafia, Wegovy, XIFAXAN, ZENPEP | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error